Icrest Biotechnologies Limited, a active public limited company, was established on 17 September 2008 in Bangalore, Karnataka, India. Engaging in preventive health services within the hospital and medical care sector, it holds CIN: U33100KA2008PLC047800. Registered under ROC Roc Bangalore. it is unlisted. It has an authorized capital of ₹2.00 Cr and a paid-up capital of ₹1.17 Cr.
It upholds a compliant status. Its leadership includes Gururaj Ananda Rao (Managing Director), Gopalakrishna Sreemushanam Anandarao (Director), Jyothsna Ananda Rao (Whole-Time Director). Past directors included Gururaj Ananda Rao, Gopalakrishna Sreemushanam Anandarao, Jyothsna Ananda Rao. It holds ₹6.85 M open charges and ₹2.77 M settled loans. Its latest AGM occurred on 26 September 2025, with the balance sheet filed on 31 March 2025. It is based at No.117, Venkateshapura Jakkur Post, Yelahanka Hobli, Bangalore, Karnataka, 560064.
U33100KA2008PLC047800
047800
17 September 2008
₹2.00 Cr
₹1.17 Cr
Roc Bangalore
Unlisted
Active
Explore comprehensive insights into Icrest Biotechnologies Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Gururaj Ananda Rao | Managing Director | 01 Dec 2010 | Current |
| Gopalakrishna Sreemushanam Anandarao | Director | 17 Sep 2008 | Current |
| Jyothsna Ananda Rao | Whole-Time Director | 17 Sep 2008 | Current |
| Basavalinga Ajaikumar Sadasivaiah | Director | 28 Feb 2024 | Current |
| Sunanda Ananda Rao | Director | 01 Mar 2010 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 08 Mar 2010 | Past |
| Pramod Abcsdd | Whole-Time Director | 05 Sep 2022 | Past |
| Pramod Abcsdd | Director | 05 Sep 2022 | Past |
| Pramod Abcsdd | Director | 06 Mar 2010 | Past |
| Pramod Abcsdd | Additional Director | 17 Sep 2010 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
International Stemcell Services Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 14.71% increase. The company also saw a substantial improvement in profitability, with a 44.29% increase in profit. The company's net worth Soared by an impressive increase of 159.09%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2022, Icrest Biotechnologies had a promoter holding of 60.85% and a public holding of 39.15%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹6,853,000.00
₹2,765,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 24 Oct 2024 | Hdfc Bank Limited | ₹6.85 M | Open |
| 05 Dec 2015 | Icici Bank Limited | ₹0.37 M | Satisfied |
| 31 Dec 2013 | Corporation Bank | ₹2.40 M | Satisfied |
Explore comprehensive loan charge details -
Unlock and access historical data on people associated with Icrest Biotechnologies, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Icrest Biotechnologies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Icrest Biotechnologies's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity Icrest Biotechnologies Limited last Annual general meeting of members was held on 26 Sep 2025 as per latest MCA records. was completed.
Icrest Biotechnologies Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Bangalore. was recorded as a recent event.
Progress on A charge with Hdfc Bank Limited amounted to Rs. 0.69 Cr with Charge ID 101016493 was registered on 24 Oct 2024. was documented.
The activity Basavalinga Ajaikumar Sadasivaiah was appointed as a Director was appointed as a Director on 28 Feb 2024 & has been associated with this company since 1 year 9 months . was completed.
Progress on A charge registered on 05 Dec 2015 via Charge ID 10619056 with Icici Bank Limited was fully satisfied on 28 Jan 2019. was documented.
The activity A charge registered on 31 Dec 2013 via Charge ID 10473800 with Corporation Bank was fully satisfied on 09 Dec 2015. was completed.
HealthCare Global Enterprises Ltd has acquired a 12% equity stake in International Stemcell Services Ltd (ISSL) - a stem cell and regenerative medicine research company based in Bengaluru. HealthCare.
The CIN of Icrest Biotechnologies Limited is U33100KA2008PLC047800.
Icrest Biotechnologies Limited is headquartered at No.117, Venkateshapura Jakkur Post, Yelahanka Hobli, Bangalore, Karnataka, 560064.
Icrest Biotechnologies Limited was incorporated on 17 September 2008.
The current directors of Icrest Biotechnologies Limited are
The primary industry of Icrest Biotechnologies Limited is Hospital And Medical Care.
Icrest Biotechnologies Limited is unlisted.
The authorized capital of Icrest Biotechnologies Limited is ₹2.00 Cr, and the paid-up capital is ₹1.17 Cr.
The compliance status of Icrest Biotechnologies Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX